10 completed, 1 terminated. 4 Phase 3, 3 Phase 2, 2 Not applicable, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 3 | Completed 3 |
| Not applicable | 2 | Completed 2 |
| Phase 4 | 2 | Completed 2 |
Follow Sevelamer Hydrochloride: new trials by email Literature Review of Sevelamer Hydrochloride trials Research Report on Sevelamer Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Different Effects of Non-calcium Phosphate Binders on Serum Calcium Sevelamer Hydrochloride, Lanthanum Carbonate - Chronic Kidney Disease | Phase 4 | Completed | Medical University of Lodz | 34 | 2018-03-01 | 2021-07-27 |
| A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia PA21, Sevelamer hydrochloride - Hemodialysis, Hyperphosphatemia | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 213 | 2013-04-23 | 2018-10-09 |
| A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis ASP1585, Sevelamer hydrochloride - Chronic Kidney Disease, Renal Dialysis | Phase 3 | Completed | Astellas Pharma Inc | 110 | 2010-01-01 | 2015-05-04 |
| Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride Fermagate, Sevelamer hydrochloride - Chronic Kidney Failure | Phase 3 | Terminated | Ineos Healthcare Limited | 1000 | 2009-07-01 | 2010-10-19 |
| Study of Phosphate Levels in Patients With Chronic Kidney Disease 1.25 g PA21 (250 mg iron), 5.0 g PA21 (1,000 mg iron), 7.5 g PA21 (1,500 mg iron) - Chronic Kidney Disease | Phase 2 | Completed | Vifor Pharma | 154 | 2008-12-01 | 2014-04-01 |
| Sevelamer Hydrochloride in Peritoneal Dialysis Patients sevelamer hydrochloride - Endstage Renal Disease | Not applicable | Completed | The University of Hong Kong | 60 | 2008-07-01 | 2020-06-18 |
| A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis ASP1585, Placebo, Sevelamer hydrochloride - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 | Completed | Astellas Pharma Inc | 156 | 2007-10-01 | 2011-03-22 |
| Head to Head Study Against Sevelamer Hydrochloride Fosrenol (Lanthanum Carbonate), Sevelamer hydrochloride - Chronic Kidney Disease, Stage 5 | Phase 3 | Completed | Shire | 182 | 2007-01-05 | 2021-06-11 |
| Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease sevelamer hydrochloride, Calcium Carbonate - End Stage Renal Disease, Hemodialysis | Not applicable | Completed | Tel-Aviv Sourasky Medical Center | 175 | 2005-02-01 | 2010-01-14 |
| Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing Sevelamer hydrochloride - Chronic Kidney Disease | Phase 2 | Completed | Genzyme, a Sanofi Company | 24 | 2003-03-01 | 2015-03-05 |
| Dialysis Clinical Outcomes Revisited (DCOR) Trial Sevelamer hydrochloride, Calcium-based phosphate binder - Chronic Kidney Disease | Phase 4 | Completed | Genzyme, a Sanofi Company | 2000 | 2001-03-01 | 2015-03-18 |
Renal Insufficiency, Chronic (7) · Hyperphosphatemia (4) · Kidney Failure, Chronic (2) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Renal Insufficiency (1)
Astellas Pharma Inc (2) · Genzyme, a Sanofi Company (2) · Ineos Healthcare Limited (1) · Kissei Pharmaceutical Co., Ltd. (1) · Medical University of Lodz (1) · Shire (1) · Tel-Aviv Sourasky Medical Center (1) · The University of Hong Kong (1) · Vifor Pharma (1)
United States (5) · Japan (3) · Bulgaria (2) · Czechia (2) · Germany (2) · Israel (2) · Poland (2) · Puerto Rico (2) · United Kingdom (2) · Belgium (1) · Brazil (1) · Croatia (1) · Estonia (1) · Hong Kong (1) · Hungary (1)
Angela YM Wang, MD, PhD (1) · Michal Nowicki, Prof.MD PhD (1) · Mona Boaz, PhD (1) · Prof. Rudolf P Wutrich, MD (1) · Talia Weinstein, MD PhD (1)
PMID 40576086, PMID 20042256, PMID 24975892, PMID 34754193, PMID 35243302
2008 (1)